Matthew A Hevey1, Ige A George2, Krunal Raval2, William G Powderly2, Andrej Spec2. 1. Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Mo. Electronic address: matthewhevey@gmail.com. 2. Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Mo.
Abstract
BACKGROUND: Cryptococcal epidemiology is changing in the modern antiretroviral era, and immune status informs outcomes. We describe the differences in clinical presentation and mortality of cryptococcosis by immune status in the antiretroviral therapy era. METHODS: We conducted a single-center retrospective cohort study of patients diagnosed with cryptococcosis from 2002 through 2017. Data included demographics, clinical features, diagnostics, and mortality. RESULTS: We identified 304 patients with Cryptococcus neoformans infections: 105 (35%) were people living with human immunodeficiency virus (HIV), 41 (13%) had a history of transplantation, and 158 (52%) were non-HIV nontransplant (NHNT). Age analysis showed that people living with HIV were younger (40 years) than transplant (53 years) and NHNT (61 years) (P < .001). Fevers and headache were more common in people living with HIV (70% and 57%) than in transplant (49% and 29%) and NHNT (49% and 38%) (P = .003 and P = .001), respectively. Meningitis was more common in people living with HIV (68%) than in transplant recipients (32%) or NHNT (39%, P < .001). Disseminated cryptococcosis was more common in people living with HIV (97%) as compared with transplant (66%) or NHNT (73%) (P < .001). Time to diagnosis from hospitalization was longer for transplant (median 2 days, interquartile range [IQR] ± 9 days) and NHNT patients (median 2 days, IQR ± 7 days) as compared with people living with HIV (median 1 day, IQR ± 2 days) (P = .003). NHNT patients had a higher risk of 90-day mortality (hazard ratio 3.3; 95% confidence interval, 1.9-5.8) as compared with people living with HIV. CONCLUSIONS: The majority of cryptococcosis occurs in NHNT patients. NHNT patients had more localized pulmonary cryptococcosis and significantly higher 90-day mortality. Cryptococcosis in NHNT patients appears to be a distinct entity that needs further study and requires a higher level of clinical suspicion than it currently receives.
BACKGROUND: Cryptococcal epidemiology is changing in the modern antiretroviral era, and immune status informs outcomes. We describe the differences in clinical presentation and mortality of cryptococcosis by immune status in the antiretroviral therapy era. METHODS: We conducted a single-center retrospective cohort study of patients diagnosed with cryptococcosis from 2002 through 2017. Data included demographics, clinical features, diagnostics, and mortality. RESULTS: We identified 304 patients with Cryptococcus neoformans infections: 105 (35%) were people living with human immunodeficiency virus (HIV), 41 (13%) had a history of transplantation, and 158 (52%) were non-HIV nontransplant (NHNT). Age analysis showed that people living with HIV were younger (40 years) than transplant (53 years) and NHNT (61 years) (P < .001). Fevers and headache were more common in people living with HIV (70% and 57%) than in transplant (49% and 29%) and NHNT (49% and 38%) (P = .003 and P = .001), respectively. Meningitis was more common in people living with HIV (68%) than in transplant recipients (32%) or NHNT (39%, P < .001). Disseminated cryptococcosis was more common in people living with HIV (97%) as compared with transplant (66%) or NHNT (73%) (P < .001). Time to diagnosis from hospitalization was longer for transplant (median 2 days, interquartile range [IQR] ± 9 days) and NHNT patients (median 2 days, IQR ± 7 days) as compared with people living with HIV (median 1 day, IQR ± 2 days) (P = .003). NHNT patients had a higher risk of 90-day mortality (hazard ratio 3.3; 95% confidence interval, 1.9-5.8) as compared with people living with HIV. CONCLUSIONS: The majority of cryptococcosis occurs in NHNT patients. NHNT patients had more localized pulmonary cryptococcosis and significantly higher 90-day mortality. Cryptococcosis in NHNT patients appears to be a distinct entity that needs further study and requires a higher level of clinical suspicion than it currently receives.
Authors: P G Pappas; J R Perfect; G A Cloud; R A Larsen; G A Pankey; D J Lancaster; H Henderson; C A Kauffman; D W Haas; M Saccente; R J Hamill; M S Holloway; R M Warren; W E Dismukes Journal: Clin Infect Dis Date: 2001-07-26 Impact factor: 9.079
Authors: Peter G Pappas; Barbara D Alexander; David R Andes; Susan Hadley; Carol A Kauffman; Alison Freifeld; Elias J Anaissie; Lisa M Brumble; Loreen Herwaldt; James Ito; Dimitrios P Kontoyiannis; G Marshall Lyon; Kieren A Marr; Vicki A Morrison; Benjamin J Park; Thomas F Patterson; Trish M Perl; Robert A Oster; Mindy G Schuster; Randall Walker; Thomas J Walsh; Kathleen A Wannemuehler; Tom M Chiller Journal: Clin Infect Dis Date: 2010-04-15 Impact factor: 9.079
Authors: Vasilios Pyrgos; Amy E Seitz; Claudia A Steiner; D Rebecca Prevots; Peter R Williamson Journal: PLoS One Date: 2013-02-15 Impact factor: 3.240
Authors: Gabriel Motoa; Amy Pate; Daniel Chastain; Sarah Mann; Gregory S Canfield; Carlos Franco-Paredes; Andrés F Henao-Martínez Journal: Ther Adv Infect Dis Date: 2020-07-08
Authors: Ana S Salazar; Matthew R Keller; Margaret A Olsen; Katelin B Nickel; Ige A George; Lindsey Larson; William G Powderly; Andrej Spec Journal: EClinicalMedicine Date: 2020-10-07
Authors: Matthew A Hevey; Ige A George; Adriana M Rauseo; Lindsey Larson; William Powderly; Andrej Spec Journal: J Clin Microbiol Date: 2020-10-21 Impact factor: 5.948
Authors: Daniel B Chastain; Andrés F Henao-Martínez; Austin C Dykes; Gregory M Steele; Laura Leigh Stoudenmire; Geren M Thomas; Vanessa Kung; Carlos Franco-Paredes Journal: Ther Adv Infect Dis Date: 2022-01-15
Authors: Daniel B Chastain; Amy Rao; Armaan Yaseyyedi; Andrés F Henao-Martínez; Thomas Borges; Carlos Franco-Paredes Journal: Pathogens Date: 2022-02-03